Histatin 5-spermidine conjugates have enhanced fungicidal activity and efficacy as a topical therapeutic for oral candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 756-766

  Tati, Swetha ^a   Li, Rui ^a   Puri, Sumant ^a   Kumar, Rohitashw ^a   Davidow, Peter ^a   Edgerton, Mira ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; HISTATIN 5; HISTATIN 5 SPERMIDINE CONJUGATE; SPERMIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA GLABRATA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; FUNGICIDAL ACTIVITY; HEMOLYSIS; HUMAN; IN VIVO STUDY; MOUSE; MOUTH FLORA; NONHUMAN; PRIORITY JOURNAL; SALIVA; SERUM; STREPTOCOCCUS; THRUSH; TONGUE;

ADMINISTRATION, MUCOSAL; ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; BIOLOGICAL TRANSPORT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS, ORAL; FEMALE; HISTATINS; HUMANS; IMMUNOCOMPROMISED HOST; MICE; MOUTH MUCOSA; OLIGOPEPTIDES; PLANKTON; SPERMIDINE;

EID: 84893474208     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01851-13     Document Type: Article

References (55)

1. Conti HR, Baker O, Freeman AF, Jang WS, Holland SM, Li RA, Edgerton M, Gaffen SL. 2011. New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome. Mucosal Immunol. 4:448-455. http://dx.doi.org/10.1038/mi. 2011.5.
2. Kanaguchi N, Narisawa N, Ito T, Kinoshita Y, Kusumoto Y, Shinozuka O, Senpuku H. 2012. Effects of salivary protein flow and indigenous microorganisms on initial colonization of Candida albicans in an in vivo model. BMC Oral Health 12:36. http://dx.doi.org/10.1186/1472-6831-12-36.
3. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177. http://dx.doi.org/10.1086/378745.
4. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM. 2005. Excess mortality, hospital stay, and cost due to candidemia: a casecontrol study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol. 26:540-547. http://dx.doi.org/10.1086/502581.
5. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE; Mycoses Study Group NIAID. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643. http://dx.doi.org/10.1086/ 376906.
6. Lupetti A, Danesi R, van 't Wout JW, van Dissel JT, Senesi S, Nibbering PH. 2002. Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin. Investig. Drugs 11:309-318. http://dx.doi.org/10.1517/13543784.11.2.309.
7. Zamperini CA, Schiavinato PC, Pavarina AC, Giampaolo ET, Vergani CE, Machado AL. 17 December 2012. Effect of human whole saliva on the in vitro adhesion of Candida albicans to a denture base acrylic resin: a focus on collection and preparation of saliva samples. J. Invest. Clin. Dent. http://dx.doi.org/10.1111/jicd.12006.
8. Oppenheim FG, Xu T, McMillian FM, Levitz SM, Diamond RD, Offner GD, Troxler RF. 1988. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J. Biol. Chem. 263:7472-7477.
9. Groenink J, Ruissen AL, Lowies D, van 't Hof W, Veerman EC, Nieuw Amerongen AV. 2003. Degradation of antimicrobial histatin-variant peptides in Staphylococcus aureus and Streptococcus mutans. J. Dent. Res. 82: 753-757. http://dx.doi.org/10.1177/154405910308200918.
10. Xu T, Levitz SM, Diamond RD, Oppenheim FG. 1991. Anticandidal activity of major human salivary histatins. Infect. Immun. 59:2549-2554.
11. Tsai H, Bobek LA. 1997. Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans. Biochim. Biophys. Acta 1336:367-369. http://dx.doi.org/10.1016/S0304-4165(97)00076-7.
12. Helmerhorst EJ, Reijnders IM, van 't Hof W, Simoons-Smit I, Veerman EC, Amerongen AV. 1999. Amphotericin B-and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob. Agents Chemother. 43:702-704.
13. Bartie KL, Devine DA, Wilson MJ, Lewis MAO. 2008. In vitro susceptibility of the Streptococcus milleri group to antimicrobial peptides. Int. Endod. J. 41:586-592. http://dx.doi.org/10.1111/j.1365-2591.2008.01404.x.
14. Tati S, Jang W, Li R, Kumar R, Puri S, Edgerton M. 2013. Histatin 5 resistance of Candida glabrata can be reversed by insertion of Candida albicans polyamine transporter-encoding genes DUR3 and DUR31. PLoS One 8:e61480. http://dx.doi.org/10.1371/journal.pone.0061480.
15. Helmerhorst EJ, Alagl AS, Siqueira WL, Oppenheim FG. 2006. Oral fluid proteolytic effects on histatin 5 structure and function. Arch. Oral Biol. 51:1061-1070. http://dx.doi.org/10.1016/j.archoralbio.2006.06.005.
16. Helmerhorst EJ, van 't Hof W, Veerman EC, Simoons-Smit I, Nieuw Amerongen AV. 1997. Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochem. J. 15:39-45.
17. Groenink J, Walgreen-Weterings E, van 't Hof W, Veerman EC, Nieuw Amerongen AV. 1999. Cationic amphipathic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral pathogens. FEMS Microbiol. Lett. 179:217-222. http://dx.doi.org/10.1111/j.1574-6968.1999. tb08730.x.
18. Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Del Prete MS, Licci A, Riva A, Lukasiak J, Scalise G. 2005. In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumoniainimmunocompromisedpatients. Antimicrob.AgentsChemother.49:1249-1252. http://dx.doi.org/10.1128/AAC.49.3.1249-1252.2005.
19. Rothstein DM, Spacciapoli P, Tran LT, Xu T, Roberts FD, Dalla Serra M, Buxton DK, Oppenheim FG, Friden P. 2001. Anticandidal activity is retained in P-113, a 12-amino-acid fragment of histatin. Antimicrob. Agents Chemother. 45:1367-1373. http://dx.doi.org/10.1128/AAC.45.5.1367-1373.2001.
20. Wei GX, Bobek LA. 2005. Human salivary mucin MUC7 12-mer-L and 12-mer-D peptides: antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells Antimicrob. Agents Chemother. 49:2336-2342. http://dx.doi.org/10.1128/AAC.49.6.2336-2342.2005.
21. Sajjan US, Tran LT, Sole N, Rovaldi C, Akiyama A, Friden PM, Forstner JF, Rothstein DM. 2001. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob. Agents Chemother. 45:3437-3444. http://dx.doi.org/10.1128/ AAC.45.12.3437-3444.2001.
22. Sugiyama K. 1993. Anti-lipopolysaccharide activity of histatins, peptides from human saliva. Experientia 49:1095-1097. http://dx.doi.org/10.1007/ BF01929920.
23. Jang WS, Bajwa JS, Sun JN, Edgerton M. 2010. Salivary histatin 5 internalization by translocation, but not endocytosis, is required for fungicidal activity in Candida albicans. Mol. Microbiol. 77:354-370. http://dx.doi.org/10.1111/j.1365-2958.2010.07210.x.
24. Kumar R, Chadha S, Saraswat D, Bajwa JS, Li RA, Conti HR, Edgerton M. 2011. Histatin 5 uptake by Candida albicans utilizes polyamine transporters Dur3 and Dur31 proteins. J. Biol. Chem. 286:43748-43758. http://dx.doi.org/10.1074/ jbc.M111.311175.
25. Igarashi K, Kashiwagi K. 2006. Polyamine modulon in Escherichia coli: genes involved in the stimulation of cell growth by polyamines. J. Biochem. 139:11-16. http://dx.doi.org/10.1093/jb/mvj020.
26. Li R, Kumar R, Tati S, Puri S, Edgerton M. 2013. Candida albicans Flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity. Antimicrob. Agents Chemother. 57:1832-1839. http://dx.doi.org/10.1128/AAC.02295-12.
27. Li XWS, Reddy MS, Baev D, Edgerton M. 2003. Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin. J. Biol. Chem. 278:28553-28561. http://dx.doi.org/10.1074/jbc.M300680200.
28. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 9th ed. Approved standard M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
29. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, Tuch BB, Andes DR, Johnson AD. 2012. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148:126-138. http://dx.doi.org/10.1016/j.cell.2011.10.048.
30. Berne S, Krizaj I, Pohleven F, Tuck T, Macek P, Sepcić K. 2002. Pleurotus and Agrocybe hemolysins, new proteins hypothetically improved in fungal fruiting. Biochim. Biophys. Acta 1570:153-159. http://dx.doi.org/10.1016/ S0304-4165(02)00190-3.
31. Park H, Myers CL, Sheppard DC, Phan QT, Sanchez AA, Edwards EJ, Filler SG. 2005. Role of the fungal Ras-protein kinaseApathway in governing epithelial cell interactions during oropharyngeal candidiasis. Cell. Microbiol. 7:499-510. http://dx.doi.org/10.1111/j.1462-5822.2004.00476.x.
32. Solis NV, Filler SG. 2012. Mouse model of oropharyngeal candidiasis. Nat. Protoc. 7:637-642. http://dx.doi.org/10.1038/nprot.2012.011.
33. Thomadaki K, Helmerhorst EJ, Tian N, Sun X, Siqueira WL, Walt DR, Oppenheim FG. 2011. Whole-saliva proteolysis and its impact on salivary diagnostics. J. Dent. Res. 90:1325-1330. http://dx.doi.org/10.1177/ 0022034511420721.
34. Sun JN, Solis NV, Phan QT, Bajwa JS, Kashleva H, Thompson A, Liu Y, Dongari-Bagtzoglou A, Edgerton M, Filler SG. 2010. Host cell invasion and virulence mediated by Candida albicans Ssa1. PLoS Pathog. 6:e1001181. http://dx.doi.org/10.1371/journal.ppat.1001181.
35. Chadwick J, Jones M, Mercer AE, Stocks PA, Ward SA, Park BK, O'Neill PM. 2010. Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in Plasmodium falciparum and HL-60 cancer cell lines. Bioorg. Med. Chem. 18: 2586-2597. http://dx.doi.org/10.1016/j.bmc.2010.02.035.
36. Liao C-P, Phanstiel O, Lasbury ME, Zhang C, Shao S, Durant PJ, Cheng BH, Lee CH. 2009. Polyamine transport as a target for treatment of Pneumocystis pneumonia. Antimicrob. Agents Chemother. 53:5259-5264. http://dx.doi.org/10. 1128/AAC.00662-09.
37. Ishijima SA, Hayama K, Burton JP, Reid G, Okada M, Matsushita Y, Abe S. 2012. Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model. Appl. Environ. Microbiol. 78:2190-2199. http://dx.doi.org/10.1128/AEM.07055-11.
38. Welling MM, Brouwer CP, van 't Hof W, Veerman EC, Nieuw Amerongen AV. 2007. Histatin-derived monomeric and dimeric synthetic peptides show strong bactericidal activity towards multidrug-resistant Staphylococcus aureus in vivo. Antimicrob. Agents Chemother. 51:3416-3419. http://dx.doi.org/10.1128/AAC. 00196-07.
39. Igarashi K, Kashiwagi K. 2010. Characteristics of cellular polyamine transport in prokaryotes and eukaryotes. Plant Physiol. Biochem. 48:506-512. http://dx.doi.org/10.1016/j.plaphy.2010.01.017.
40. Higashi K, Sakamaki Y, Herai E, Demizu R, Uemura T, Saroj SD, Zenda R, Terui Y, Nishimura K, Toida T, Kashiwagi K, Igarashi K. 2010. Identification and functions of amino acid residues in PotB and PotC involved in spermidine uptake activity. J. Biol. Chem. 285:39061-39069. http://dx.doi.org/10.1074/jbc.M110. 186536.
41. Ruissen AL, Groenink J, Helmerhorst EJ, Walgreen-Weterings E, van 't Hof W, Veerman EC, Nieuw Amerongen AV. 2001. Effects of histatin 5 and derived peptides on Candida albicans. Biochem. J. 356:361-368. http://dx.doi.org/10. 1042/0264-6021:3560361.
42. Den Hertog AL, Wong Fong Sang HW, Kraayenhof R, Bolscher JG, van 't Hof W, Veerman EC, Nieuw Amerongen AV. 2004. Interactions of histatin 5 and histatin 5-derived peptides with liposome membranes: surface effects, translocation and permeabilization. Biochem. J. 379:665-672. http://dx.doi.org/10.1042/BJ20031785.
43. Groot F, Sanders RW, ter Brake O, Nazmi K, Veerman EC, Bolscher JG, Berkhout B. 2006. Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry. J. Virol. 80:9236-9243. http://dx.doi.org/10.1128/JVI.00796-06.
44. Meiller TF, Hube B, Schild L, Shirtliff ME, Scheper MA, Winkler R, Ton A, Jabra-Rizk MA. 2009. A novel immune evasion strategy of Candida albicans: proteolytic cleavage of a salivary antimicrobial peptide. PLoS One 4:e5039. http://dx.doi.org/10.1371/journal.pone.0005039.
45. Sun X, Salih E, Oppenheim FG, Helmerhorst EJ. 2009. Kinetics of histatin proteolysis in whole saliva and the effect on bioactive domains with metal-binding, antifungal, and wound-healing properties. FASEB J. 23:2691-2701. http://dx.doi.org/10.1096/fj.09-131045.
46. Campese M, Sun X, Bosch JA, Oppenheim FG, Helmerhorst EJ. 2009. Concentration and fate of histatins and acidic proline-rich proteins in the oral environment. Arch. Oral Biol. 54:345-353. http://dx.doi.org/10.1016/j. archoralbio.2008.11.010.
47. Peters BM, Zhu J, Fidel PL, Jr, Scheper MA, Hackett W, El Shaye S, Jabra-Rizk MA. 2010. Protection of the oral mucosa by salivary histatin-5 against Candida albicans in an ex vivo murine model of oral infection. FEMS Yeast Res. 10:597-604. http://dx.doi.org/10.1111/j.1567-1364.2010.00632.x.
48. Brewer D, Lajoie G. 2002. Structure-based design of potent histatin analogues. Biochemistry 41:5526-5536. http://dx.doi.org/10.1021/bi015926d.
49. Oudhoff MJ, Kroeze KL, Nazmi K, van den Keijbus PA, van 't Hof W, Fernandez-Borja M, Hordijk PL, Gibbs S, Bolscher JG, Veerman EC. 2009. Structure-activity analysis of histatin, a potent wound healing peptide from human saliva: cyclization of histatin potentiates molar activity 1,000-fold. FASEB J. 23:3928-3935. http://dx.doi.org/10.1096/fj.09-137588.
50. Kulak Y, Arikan A, Delibalta N. 1994. Comparison of three different treatment methods for generalized denture stomatitis. J. Prosthet. Dent. 72:283-288. http://dx.doi.org/10.1016/0022-3913(94)90341-7.
51. Laudenbach JM, Epstein JB. 2009. Treatment strategies for oropharyngeal candidiasis. Expert Opin. Pharmacother. 10:1413-1421. http://dx.doi.org/10.1517/ 14656560902952854.
52. Rautemaa R, Ramage G. 2011. Oral candidosis-clinical challenges of a biofilm disease. Crit. Rev. Microbiol. 37:328-336. http://dx.doi.org/10.3109/ 1040841X.2011.585606.
53. Hata K, Horii T, Miyazaki M, Watanabe NA, Okubo M, Sonoda J, Nakamoto K, Tanaka K, Shirotori S, Murai N, Inoue S, Matsukura M, Abe S, Yoshimatsu K, Asada M. 2011. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob. Agents Chemother. 55:4543-4551. http://dx.doi.org/10. 1128/AAC.00366-11.
54. Fonzi WA, Irwin MY. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
55. Joly S, Maze C, McCray PB, Jr, Guthmiller JM. 2004. Human betadefensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 42:1024-1029. http://dx.doi.org/10.1128/JCM.42.3.1024-1029. 2004.